Catalyst Wire Dossier Catalyst Wire Dossier

Dolutegravir/Lamivudine

dolutegravir/lamivudine · ViiV Healthcare
Drug timelines are a Plus or Pro feature.

7 regulatory and trial events tracked for Dolutegravir/Lamivudine, covering 2019-02-21 to 2025-09-24. Get the full timeline:

Most recent: Clinical Trial Update: Dolutegravir/Lamivudine Dual Therapy for ART-naïve People With HIV and TB Receiving Rifampin-based TB Treatment [Phase 3]

See pricing